Natarajan Sethuraman
CIK: 0001873394
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Entrada Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Sep 2, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct2.1K shares at avg. $7.14$15K - May 4, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct25.9K shares at avg. $15.39$399K - Mar 3, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct7.6K shares at avg. $11.76$89K - Mar 2, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct3.9K shares at avg. $11.66$45K - Mar 1, 2026TRDA
Entrada Therapeutics, Inc.
Award(A)Direct55.8K shares- - Sep 2, 2025TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct1.8K shares at avg. $5.43$10K - Mar 3, 2025TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct6.1K shares at avg. $11.68$72K - Mar 1, 2025TRDA
Entrada Therapeutics, Inc.
Award(A)Direct60.8K shares- - Dec 3, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct11.7K shares at avg. $20.15$236K - Dec 2, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct4.1K shares at avg. $20.26$83K - Nov 29, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct100 shares at avg. $20.00$2K - Nov 13, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct2.7K shares at avg. $20.04$54K - Nov 11, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct1.4K shares at avg. $20.01$28K - Nov 6, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct2.7K shares at avg. $19.32$53K - Nov 6, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct9.6K shares at avg. $18.71$179K - Nov 5, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct5.2K shares at avg. $18.18$94K - Nov 4, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct749 shares at avg. $18.02$13K - Oct 16, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct600 shares at avg. $18.00$11K - Sep 9, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct2.6K shares at avg. $15.09$40K - Sep 6, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct600 shares at avg. $15.24$9K - Sep 5, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct167 shares at avg. $15.13$3K - Sep 4, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct955 shares at avg. $15.42$15K - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct14 shares at avg. $17.70$247.828 - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct151 shares at avg. $16.93$3K - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct469 shares at avg. $15.76$7K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 2,079 | $7.14 | $14,852 | Direct |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 25,907 | $15.39 | $398,810 | Direct |
| Mar 3, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 7,577 | $11.76 | $89,078 | Direct |
| Mar 2, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 3,898 | $11.66 | $45,442 | Direct |
| Mar 1, 2026 | TRDA Entrada Therapeutics, Inc. | Award(A) | 55,800 | - | $0 | Direct |
| Sep 2, 2025 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 1,760 | $5.43 | $9,557 | Direct |
| Mar 3, 2025 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 6,138 | $11.68 | $71,683 | Direct |
| Mar 1, 2025 | TRDA Entrada Therapeutics, Inc. | Award(A) | 60,800 | - | - | Direct |
| Dec 3, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 11,703 | $20.15 | $235,786 | Direct |
| Dec 2, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 4,088 | $20.26 | $82,834 | Direct |
| Nov 29, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 100 | $20.00 | $2,000 | Direct |
| Nov 13, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 2,700 | $20.04 | $54,109 | Direct |
| Nov 11, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 1,409 | $20.01 | $28,191 | Direct |
| Nov 6, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 2,745 | $19.32 | $53,024 | Direct |
| Nov 6, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 9,554 | $18.71 | $178,752 | Direct |
| Nov 5, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 5,171 | $18.18 | $94,006 | Direct |
| Nov 4, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 749 | $18.02 | $13,498 | Direct |
| Oct 16, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 600 | $18.00 | $10,800 | Direct |
| Sep 9, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 2,642 | $15.09 | $39,862 | Direct |
| Sep 6, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 600 | $15.24 | $9,141 | Direct |
| Sep 5, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 167 | $15.13 | $2,526 | Direct |
| Sep 4, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 955 | $15.42 | $14,729 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 14 | $17.70 | $248 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 151 | $16.93 | $2,556 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 469 | $15.76 | $7,392 | Direct |
1-25 of 25 transactions
About Sethuraman Natarajan
Sethuraman Natarajan (SEC CIK 0001873394) files insider reports with the SEC as President, Research & Develop. of Entrada Therapeutics, Inc. (TRDA).
Signal8 holds 11 ownership filings by Sethuraman Natarajan, all Form 4s, filed between Sep 5, 2024 and Sep 3, 2026. Those filings report 25 transactions, from Sep 3, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Sethuraman Natarajan's filings is in BOSTON, MA.
Recent filings by Sethuraman Natarajan
- Sep 2, 2026: Tax withholding of TRDA shares (Form 4, code F).
- May 4, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Mar 3, 2026: Tax withholding of TRDA shares (Form 4, code F).
- Mar 2, 2026: Tax withholding of TRDA shares (Form 4, code F).
- Mar 1, 2026: Grant or award of TRDA shares (Form 4, code A).
Other insiders filing for Entrada Therapeutics, Inc. (TRDA)
- MPM BIOVENTURES 2018, L.P., 10% Owner
- MPM BioVentures 2014, L.P., 10% Owner
- Doshi Dipal, CEO
- Dowden Nathan J, President & COO
- WENTWORTH KORY JAMES, Chief Financial Officer
- PARMAR KUSH, Director